Hit By The Pandemic, Trevena Restarts Opioid Use Disorder Program After More Than A Year

by Vandana Singh, Benzinga Editor

June 16, 2021 7:30 AM | 1 min read |

Trevena Inc TRVN has announced that the National Institute on Drug Abuse (NIDA), part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734.
The Company has collaborated with NIDA to evaluate TRV734 as potential maintenance therapy for opioid use disorder.
The study was paused in March 2020 due to the COVID-19 pandemic.
The randomized, double-blind, four-period, placebo- and positive-controlled study will enroll approximately 50 opioid-dependent patients undergoing stable methadone maintenance therapy.
The primary outcome is the suppression of withdrawal symptoms.
Price Action: TRVN shares are up 5.45% at $2.13 during the premarket session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care Small Cap FDA General Briefs Opioids

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.